Abstract
Hypertension (HTN) and chronic kidney disease (CKD) often coexist sharing common pathophysiological factors that both in combination and separately induce fibrotic changes in the heart provoking atrial fibrillation (AF). AF, per se, is associated with a 4- to 5-fold increased risk of stroke and a 2-fold increased risk of all-cause death. The co-existence of AF with HTN and renal dysfunction considerably increases morbidity and mortality. Management of AF in hypertensive patients with CKD is complex and multidisciplinary, since these patients have both a prothrombotic state and a coagulopathy with an increased tendency for bleeding. Novel oral anticoagulants such as dabigatran, rivaroxaban and apixaban offer better efficacy and safety especially in patients without optimal treatment with vitamin K antagonists.
Keywords: Atrial fibrillation, anticoagulants, chronic kidney disease, hypertension.
Graphical Abstract
Current Vascular Pharmacology
Title:Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad
Volume: 13 Issue: 1
Author(s): Dimitris Tsiachris, Costas Tsioufis, Patrizio Mazzone, Niki Katsiki and Christodoulos Stefanadis
Affiliation:
Keywords: Atrial fibrillation, anticoagulants, chronic kidney disease, hypertension.
Abstract: Hypertension (HTN) and chronic kidney disease (CKD) often coexist sharing common pathophysiological factors that both in combination and separately induce fibrotic changes in the heart provoking atrial fibrillation (AF). AF, per se, is associated with a 4- to 5-fold increased risk of stroke and a 2-fold increased risk of all-cause death. The co-existence of AF with HTN and renal dysfunction considerably increases morbidity and mortality. Management of AF in hypertensive patients with CKD is complex and multidisciplinary, since these patients have both a prothrombotic state and a coagulopathy with an increased tendency for bleeding. Novel oral anticoagulants such as dabigatran, rivaroxaban and apixaban offer better efficacy and safety especially in patients without optimal treatment with vitamin K antagonists.
Export Options
About this article
Cite this article as:
Tsiachris Dimitris, Tsioufis Costas, Mazzone Patrizio, Katsiki Niki and Stefanadis Christodoulos, Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad, Current Vascular Pharmacology 2015; 13 (1) . https://dx.doi.org/10.2174/1570161112666140519154615
DOI https://dx.doi.org/10.2174/1570161112666140519154615 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nephro-Protective Effect of Cortex Lycii Radicis Extracts in Streptozotocin- Induced Diabetic Rats
Current Signal Transduction Therapy Disulfide Bridges in Defensins
Current Topics in Medicinal Chemistry Vascular Sex Hormone Receptors and their Specific Modulators in the Management of Postmenopausal Cardiovascular Disease
Current Hypertension Reviews The Endothelial-Mesenchymal Transition (EndMT) and Tissue Regeneration
Current Stem Cell Research & Therapy Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?
Current Pharmaceutical Biotechnology Importance of Oxidative Damage on the Electron Transport Chain for the Rational Use of Mitochondria-Targeted Antioxidants
Mini-Reviews in Medicinal Chemistry Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design The Therapeutic Applications of Exosomes in Different Types of Diseases: A Review
Current Molecular Medicine Vascular Effects of Insulin and Their Relation to Endothelial Dysfunction, Insulin Resistance and Hypertension
Current Hypertension Reviews Anti-Apoptotic Effect of Human Telomerase Reverse Transcriptase on Endothelial Cells under Oxidative Stress, Independent of Telomere Elongation and Telomerase Activity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology Uremia, Atherothrombosis and Malnutrition: The Role of L-arginine- Nitric Oxide Pathway
Cardiovascular & Hematological Disorders-Drug Targets Behavioral Experimental Paradigms for the Evaluation of Drug’s Influence on Cognitive Functions: Interpretation of Associative, Spatial/Nonspatial and Working Memory
CNS & Neurological Disorders - Drug Targets The Bioactive Compounds Obtained from Hawthorn, Chokeberry, Rosehip and Bilberry by Microfiltration
Current Bioactive Compounds Pharmacological Treatment of Hypertension: Effects in Endothelial Function
Current Hypertension Reviews Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy
Current Cancer Drug Targets Therapeutic Angiogenesis for Limb Ischemia Using Angiogenic Growth Factors and Carriers
Current Tissue Engineering (Discontinued) Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design